We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Laboratorios Farmaceutocos Rovi SA (ROVI) EUR0.06

Sell:€62.00 Buy:€62.95 Change: €1.15 (1.82%)
Market closed |  Prices as at close on 13 December 2024 | Switch to live prices |
Sell:€62.00
Buy:€62.95
Change: €1.15 (1.82%)
Market closed |  Prices as at close on 13 December 2024 | Switch to live prices |
Sell:€62.00
Buy:€62.95
Change: €1.15 (1.82%)
Market closed |  Prices as at close on 13 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Contact details

Address:
C/ Julian Camarillo, 35
MADRID
28037
Spain
Telephone:
+34 (913) 756230
Website:
https://www.rovi.es/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ROVI
ISIN:
ES0157261019
Market cap:
€3.24 billion
Shares in issue:
51.82 million
Sector:
Pharmaceuticals
Exchange:
Madrid Stock Exchange
Country:
Spain
Currency:
Euro
Indices:
n/a

Key personnel

  • Juan Lopez-Belmonte Encina
    Executive Chairman of the Board, Chief Executive Officer
  • Javier Lopez-Belmonte Encina
    First Executive Vice Chairman of the Board, Chief Financial Officer, General Manager of Industrial Operations
  • Ivan Jorge Lopez-Belmonte Encina
    Second Executive Vice Chairman of the Board, Chief Commercial and Development Officer
  • Beatriz Avila Alcalde
    Sales Director
  • Maria Rosario Perucha Perez
    Marketing Director
  • Francisco Javier Angulo Garcia
    Human Resources Manager
  • Mercedes Benitez Del Castillo Sanchez
    Chief Legal Officer
  • Pedro Carretero Trillo
    Hospital Network Manager
  • Miguel Angel Castillo San Roman
    International and Business Development Manager
  • Marta Garcia Molynuex
    Records Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.